Catalog No.S1340 Synonyms: AM-1155, CG5501, BMS-206584

For research use only.

Gatifloxacin (AM-1155, CG5501, BMS-206584) is an antibiotic of the fourth-generation fluoroquinolone family, and inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.

Gatifloxacin Chemical Structure

CAS No. 112811-59-3

Selleck's Gatifloxacin has been cited by 2 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Other Topoisomerase Products

Biological Activity

Description Gatifloxacin (AM-1155, CG5501, BMS-206584) is an antibiotic of the fourth-generation fluoroquinolone family, and inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.
DNA gyrase [1] topoisomerase IV [1]
In vitro

Gatifloxacin has somewhat better in vitro activity against M. tuberculosis than moxifloxacin, and both are much more active than levofloxacin. Gatifloxacin is against M. tuberculosis ATCC 35801 with MICs of 0.125 μg/mL. [1] Gatifloxacin possesses potent inhibitory activities against bacterial type II topoisomerases (50% inhibitory concentration [IC50] = 13.8 mg/mL for S. aureus topoisomerase IV; IC50 = 0.109 mg/mL for E. coli DNA gyrase) but the lowest activity against HeLa cell topoisomerase II (IC50 = 265 mg/mL) among the quinolones tested. [2] Gatifloxacin is synergic with the beta-lactams piperacillin, cefepime and meropenem, and with gentamicin against some drug-resistant pathogens. [3] Gatifloxacin, an 8-methoxyfluoroquinolone, inhibits a staphylococcal efflux pump. Gatifloxacin combined with Ciprofloxacinplus shows synergy by the Etest method for 6 (19%) of the 31 P. aeruginosa isolates using a summation fractional inhibitory concentration of < or = 0.5 for synergy. [4] Gatifloxacin is two-fold less potent than ciprofloxacin, and the same as or two-fold more potent than ofloxacin against Enterobacteriaceae. Gatifloxacin is highly potent (MIC90s, 0.03-0.06 mg/L) against Haemophilus influenzae, Legionella spp., Helicobacter pylori and has at least eight-fold better anti-chlamydial and anti-mycoplasma potency (gatifloxacin MIC90s, 0.13 mg/L). [5]

In vivo Gatifloxacin decreases the serum glucose concentration in both normal and diabetic rats. Gatifloxacin results in an increase in the serum epinephrine concentration in both normal and diabetic rats. [6]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 375.39


CAS No. 112811-59-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00905762 Completed Drug: Gatifloxacin|Drug: Moxifloxacin|Drug: Besifloxacin Healthy Bausch & Lomb Incorporated March 2009 Phase 1
NCT00335231 Withdrawn Drug: gatifloxacin ophthalmic (ZYMAR) Endophthalmitis Queen''s University June 2006 Not Applicable
NCT00382460 Completed Drug: PRAVASTATIN SODIUM Actue Coronary Syndromes Bristol-Myers Squibb November 2000 Phase 4

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Gatifloxacin | Gatifloxacin ic50 | Gatifloxacin price | Gatifloxacin cost | Gatifloxacin solubility dmso | Gatifloxacin purchase | Gatifloxacin manufacturer | Gatifloxacin research buy | Gatifloxacin order | Gatifloxacin mouse | Gatifloxacin chemical structure | Gatifloxacin mw | Gatifloxacin molecular weight | Gatifloxacin datasheet | Gatifloxacin supplier | Gatifloxacin in vitro | Gatifloxacin cell line | Gatifloxacin concentration | Gatifloxacin nmr